Alkermes plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALKS research report →
Range $50 – $68
Price Chart
About the company
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
- CEO
- Blair Jackson
- IPO
- 1991
- Employees
- 2,050
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on ALKS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.55B
- P/E
- 15428.33
- Fwd P/E
- 75.61
- PEG
- -154.79
- P/S
- 4.44
- P/B
- 4.17
- EV/EBITDA
- 48.79
- Div Yield
- 0.00%
- Gross Margin
- 82.89%
- Op Margin
- 3.66%
- Net Margin
- -0.02%
- ROE
- -0.02%
- ROIC
- -0.05%
Latest fiscal year · YoY change
- Revenue
- $1.48B-5.2%
- Gross Profit
- $1.28B-2.5%
- Op Income
- $253.96M
- Net Income
- $241.66M-34.2%
- EPS
- $1.47-33.8%
- OCF Growth
- +18.6%
- FCF Growth
- +18.4%
- 52W High
- $55.67
- 52W Low
- $27.00
- 50D MA
- $43.71
- 200D MA
- $41.36
- Beta
- 0.27
- RSI (14)
- 55
- Avg Volume
- 1.89M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alkermes posted strong Q3 sales growth driven by its proprietary portfolio and laid out an increasingly pipeline-heavy strategy centered on orexin programs.· November 3, 2026
- Proprietary product net sales rose 31% year over year to $417.3 million, led by LUMRYZ, VIVITROL, ARISTADA, and LYBALVI.
- Total revenue was $480.1 million; GAAP net income was $16.3 million and adjusted EBITDA was $120.1 million.
- Management reiterated full-year sales guidance, including VIVITROL at $460 million to $480 million, ARISTADA at $365 million to $385 million, LYBALVI at $380 million to $400 million, and LUMRYZ total sales of $350 million to $370 million.
- The company is leaning into orexin R&D, with elixorexan Phase 3 narcolepsy studies underway and additional trials in idiopathic hypersomnia, ADHD, MDD, and fatigue.
- Management said 2026 financial expectations are unchanged and expects stronger cash generation and adjusted EBITDA in 2027 as transaction-related costs roll off.
Q3 total revenue was $480.1 million, including $417.3 million of proprietary product net sales and $62.9 million of manufacturing and royalty revenue. Proprietary product sales increased 31% year over year. Gross margin specifics were not stated, but cost of goods sold was $94.2 million versus $51.6 million in Q3 of the prior year; R&D was $121.1 million versus $81.7 million, and SG&A was $208.5 million versus $171.8 million. GAAP net income was $16.3 million, EBITDA was $63 million, and adjusted EBITDA was $120.1 million. The company ended the quarter with approximately $787 million in cash and investments. Full-year 2026 guidance was reiterated: VIVITROL $460 million to $480 million, ARISTADA $365 million to $385 million, LYBALVI $380 million to $400 million, total LUMRYZ sales $350 million to $370 million with Alkermes recognizing $315 million to $335 million, fourth-quarter proprietary portfolio net sales of $400 million to $420 million, and proprietary portfolio net sales of nearly $1.6 billion for 2026 overall. Management also said 2026 financial expectations provided in July were unchanged.
Blair Jackson framed the quarter as the start of a new chapter, emphasizing execution, disciplined capital allocation, and the company’s pipeline as the biggest long-term value driver. He repeatedly pointed to orexin as the key strategic platform, saying Alkermes is still early in understanding the biology but is already generating clinical data across sleep, psychiatry, and neurology. His tone was confident and optimistic, with a clear message that the company wants to pair commercial strength with a broader R&D engine.
Joshua Reed said the company delivered solid financial results supported by the commercial portfolio and disciplined management, with total revenue of $480.1 million and adjusted EBITDA of $120.1 million. He highlighted higher quarter-over-quarter and year-over-year spending tied to the Avadel transaction, including COGS of $94.2 million, R&D of $121.1 million, and SG&A of $208.5 million. He also said the balance sheet remained strong at approximately $787 million in cash and investments, reiterated 2026 expectations, and said 2027 should see lower COGS and a broadly similar SG&A base excluding transaction-related costs, while R&D rises with a larger program slate.
Analysts focused heavily on the orexin pipeline, especially idiopathic hypersomnia, ADHD, and MDD. Management said the IH readout should provide both once-daily and split-dose data, and that the company wants to move quickly to Phase 3 after discussing the results with regulators. On ADHD, Blair Jackson pushed back on the idea that the program must match stimulants directly, saying there is a commercially attractive range of efficacy outcomes and that the Phase 1b data supported the current dose range and study design. On MDD, he argued orexin agonism is fundamentally different from orexin antagonism because Alkermes is trying to treat mood directly and will study an enriched subgroup with excessive daytime sleepiness.
The call showed broad commercial momentum, with all four proprietary products contributing and management raising confidence in LUMRYZ, VIVITROL, ARISTADA, and LYBALVI. The pipeline also looks active and data-rich, with multiple orexin catalysts ahead, including IH, narcolepsy, ADHD, MDD, and fatigue programs. Management sounded upbeat about expanding orexin into new indications and believes the commercial business gives it the financial flexibility to fund that expansion.
The biggest risks are clinical and execution-related: the orexin strategy depends on multiple upcoming readouts, and management acknowledged that Phase 2 results will determine how fast and how far the programs move. There is also competitive and pricing uncertainty in sleep medicine, especially with Takeda entering the market and questions about payer dynamics for oxybate and orexin products. In addition, 2026 expenses are being distorted by Avadel-related costs, and management said 2027 assumptions are still to be fully detailed later.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.5%
- Shares Outstanding
- 168.04M
- Float Shares
- 155.47M
of shares held by institutions
439 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ALKS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 28.70M | ▼ 532.38K |
| Vanguard Group Inc | 18.01M | ▼ 172.15K |
| State Street Corp | 10.13M | ▲ 970.67K |
| Baker Bros. Advisors LP | 10.01M | 0 |
| Vanguard Portfolio Management LLC | 9.46M | ▼ 31.53K |
| Vanguard Capital Management LLC | 7.50M | ▼ 11.69K |
| Price T Rowe Associates Inc | 6.74M | ▲ 2.07M |
| Renaissance Technologies LLC | 6.49M | ▲ 32.90K |
| Geode Capital Management, LLC | 4.44M | ▼ 40.54K |
| Deep Track Capital, LP | 4.00M | ▲ 409.68K |
| Holocene Advisors, LP | 3.60M | ▲ 1.28M |
| Dimensional Fund Advisors LP | 3.15M | ▼ 1.04M |
Held by 523 ETFs
Biggest fund positions in ALKS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Gaffin David Joseph | sell | 2,035 |
| Oct 8, 26 | Reed Joshua | other | 9,164 |
| Oct 8, 26 | Reed Joshua | other | 9,164 |
| Oct 8, 26 | Reed Joshua | other | 4,069 |
| Oct 7, 26 | Whitaker Anne Clem | other | 17,998 |
| Oct 7, 26 | Whitaker Anne Clem | other | 7,239 |
| Oct 2, 26 | Gaffin David Joseph | sell | 2,034 |
| Sep 14, 26 | Whitaker Anne Clem | other | 0 |
| Sep 3, 26 | Gaffin David Joseph | sell | 2,034 |
| Sep 1, 26 | Hopkinson Craig C. | other | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALKS coverage
Recent articles, reports, and earnings notes.
No research on ALKS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALKS report →Bessemer Group Inc. Acquires 202,616 Shares of Alkermes plc $ALKS
defenseworld.net · Nov 19
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
defenseworld.net · Nov 17
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
marketbeat.com · Nov 16
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
businesswire.com · Nov 5
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
What Alkermes (ALKS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
zacks.com · Nov 3
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.